MedTrace Logo

Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin

NCT00565500 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2007-11-30

No results posted yet for this study

Summary

Study design: Single center, placebo-controlled, double blind, parallel groups. To evaluate the potential interaction between aspirin and ibuprofen or celecoxib in patients with osteoarthritis (OA) and documented stable ischemic heart disease, a total of 24 patients chronically treated with aspirin will be randomly assigned to one of the 3 treatment groups: 1) celecoxib 200 mg bid; 2) ibuprofen 600 mg tid; 3) placebo.

Conditions

Interventions

DRUG

celecoxib

celecoxib capsules 200 mg bid for 1 week

DRUG

ibuprofen

ibuprofen tablets 600 mg tid for 1 week

DRUG

placebo

placebo capsules tid for 1 week

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Chieti

    lead OTHER

Principal Investigators

  • Raffaele De Caterina, MD, PhD · Institute of Cardiology, G. d'Annunzio University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Completion
2005-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565500 on ClinicalTrials.gov